Recent

% | $
Quotes you view appear here for quick access.

ImmunoCellular Therapeutics, Ltd. Message Board

  • fuiop2008@gmail.com fuiop2008 Jun 24, 2013 7:33 PM Flag

    parallelstudy

    Induction of CD8+ T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma

    "Two patients (patients 1 and 20) experienced objective clinical tumor regressions (response rate, 9%).
    Nine patients (41%; four and five with GBM and AG, respectively) are progression free for at least 12 months."

    very little about ict 107 design is different so this bodes ill for the future phase ii multi arm study considering the unusually high antigen frequency in the single arm pi study

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
IMUC
0.1195-0.0007(-0.58%)Aug 26 4:00 PMEDT